Microsoft word - iontophoresis for plantar fasciitis
American International College Effectiveness of iontophoretic administration of dexamethasone on musculoskeletal pain, specifically plantar fasciitis.
Effectiveness of iontophoretic administration of dexamethasone on
musculoskeletal pain, specifically plantar fasciitis.
1. Iontophoretic administration of dexamethasone is effective in pain
reduction of plantar fasciitis in the acute phase.
2. Iontophoretic administration of dexamethasone is no more effective than
manual physical therapy and exercise for pain reduction of chronic
Does iontophoretic administration of dexamethasone decrease pain in patients
I: Iontophoretic administration of dexamethasone
I used PubMed, Cochrane Library, Medline, PEDro, and CINAHL to search for
studies with high levels of evidence such as systematic reviews or randomized
Key Words : Iontophoresis, plantar fasciitis, dexamethasone Limits Selected: None, but looked for highest levels of evidence # of Hits: PubMed – 14 (2 relevant)
1. Gudeman SD, Eisele SA, Heidt RS, Jr, Colosimo AJ, Stroupe AL. Treatment of
plantar fasciitis by iontophoresis of 0.4% dexamethasone. A randomized, double-
blind, placebo-controlled study. Am J Sports Med. 1997 May-Jun; 25(3): 312-316
2. Osborne HR, Allison GT. Treatment of plantar fasciitis by LowDye taping and
iontophoresis: short term results of a double blinded, randomised, placebo
controlled clinical trial of dexamethasone and acetic acid. Br J Sports Med. 2006
3. Torro J, Brunetti L, Patel MK, M.D. Iontophoretic administration of
dexamethasone for musculoskeletal pain. The Journal of Musculoskeletal
Medicine. 2011;28(11):410-413,418-421.
1. Subjects were randomly assigned to two groups. Group 1 was the control
group which received iontophoresis to the plantar fascia but only a buffered
saline solution was delivered. Group 2 was the experimental group and received
iontophoresis to the plantar fascia with a 0.4% dexamethasone sodium
phosphate USP. 6 treatments were administered to each group over two weeks
and outcome measures were taken before and after the 6 treatments. The
outcome measure of choice for this study was the Maryland Foot Score (MFS)
which assesses both pain and function on a 100 point scale.
2. Subjects were randomly assigned to one of three groups using computer
generated block randomization. Each group received iontophoresis. Group 1
received 0.4% dexamethasone, group 2 received 5% acetic acid, or a placebo
treatment of 0.9% NaCl. Every group also received LowDye
taping. Measurements of primary outcomes were done at 2 week intervals
(baseline, after treatment, at follow up) and patients were surveyed at the follow
up to see which drug they thought was used in order to determine if masking had
been successful. The outcome measure of choice for this study was the Visual
3: A medical literature search was conducted in MEDLINE/PubMed, Web of
Science, International Pharmaceutical Abstracts,and Google Scholar; the terms
"dexamethasone," "iontophoresis," and "musculoskeletal disorders" were used to
identify relevant original research articles. Priority was placed on data derived
from humans, especially those obtained from randomized controlled trials. A
total of 13 clinical trials that met the inclusion/exclusion criteria were reviewed
1: Strengths- Subjects were randomly assigned to each group, inclusion and
exclusion criteria were defined, testers were blinded to pre-treatment baseline
MFS, subjects were blinded to treatment received
Weaknesses- Patient populations were not similar at baseline (32 women, 7
men), data collectors were not blinded to group membership.
2: Strengths- Randomization of subjects to treatment groups occurred. Subjects
were blinded to group assignment, inclusion and exclusion criteria were clearly
Weaknesses- Patient populations were not similar at baseline.
3: Strengths- Randomized controlled trials were lowest level of evidence, 8
different musculoskeletal conditions considered
Weaknesses- Only 3 studies on plantar fasciitis
1: Overall, the results of the study were that patient’s pain decreased and
function increased post intervention with a statistically significant P-value of
0.022. 95% percent of patients had excellent results and 5% had good/fair
results. Confidence intervals of 95% reported in table form. Numbers needed to
treat were not reported, however a cost analysis was shown. This study had a
2: The results of this study show that dexamethasone and acetic acid provide
equal benefits over placebo treatments. Statistical significance was set at p<.05.
Confidence intervals of 95% were reported in table form of p= .025. Numbers
needed to treat were not reported in this study.
3: These results of this study suggest that iontophoresis may be beneficial in the
short-term (acute-phase) management of plantar heel pain, but no more
beneficial than manual physical therapy plus exercise in the long-term.
Since the results of the literature conclude that iontophoretic administration of
dexamethasone is beneficial for pain management in the acute phase of healing
of plantar fasciitis, I would incorporate it into my practice. However, if my patient
presented with plantar fasciitis that was in the chronic stage, I would likely choose
a different intervention. It can also be beneficial because it circumvents the
toxicities associated with injections of dexamethasone.
I would use the Lower Extremity Functional Scale (LEFS) or the Foot Function
The role and source of 5P-deoxyadenosyl radical in a carbon skeletonrearrangement catalyzed by a plant enzymeSandrine Ollagnier, Eric Kervio, Jaènos Reètey*Lehrstuhl fuër Biochemie, Institut fuër Organische Chemie, Universitaët Karlsruhe, Kaiserstr. 12, D-76128 Karlsruhe, GermanyReceived 15 August 1998; received in revised form 24 September 1998Abstract The last step in the biosynthesi
Current Protocols in the Hematology /Oncology Clinic as of 06/01/2013 Breast 1. AMGEN 20110147 : Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim 2. NSABP B-43 : A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation